Skip to main content
. 2023 Jun 16;11(6):1735. doi: 10.3390/biomedicines11061735

Figure 5.

Figure 5

LNP-ASL CDS2 mRNA treatment leads to survival benefit in the ASLD mouse model. (a,b) Kaplan–Meier curves for ASLNeo/Neo mice (N = 5/group) treated weekly or bi-weekly with LNP-ASL mRNA while challenged with a high-protein diet. Data from 4 dose levels and PBS control animals are shown; (c,d) the change in mouse body weight over time is shown for each dose group. A pre-specified loss of 20% body weight (BW) (dotted line) triggered animal sacrifice.